News
05-17-2011, 11:21 PM
Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.
More... (http://www.news-medical.net/news/20110518/Amgen-announces-primary-results-from-XGEVA-Phase-3-trial-in-castrate-resistant-prostate-cancer.aspx)
More... (http://www.news-medical.net/news/20110518/Amgen-announces-primary-results-from-XGEVA-Phase-3-trial-in-castrate-resistant-prostate-cancer.aspx)